Cargando…
MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis
BACKGROUND: Recurrent respiratory papillomatosis (RRP) or laryngeal papillomatosis is a disease caused by papillomavirus infection. METHODS: In this phase I/II clinical trial, we evaluated the efficacy of the modified vaccinia Ankara (MVA) E2 virus in the treatment of RRP. Twenty‐nine patients (18 f...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590416/ https://www.ncbi.nlm.nih.gov/pubmed/30605254 http://dx.doi.org/10.1002/hed.25477 |